In response to the urgent need to accelerate the discovery and development of new drugs to fight tuberculosis (TB), a landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a non-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, was announced at the Pacific Health Summit.
The two organisations have agreed to share their expertise and resources in the development of “TMC207”, an anti-tuberculosis drug with a new mechanism of action.
The interim data from an ongoing Phase II study of TMC207 were recently published in the New England Journal of Medicine. In the placebo-controlled study of 47 patients with multidrug-resistant TB (MDR-TB), it was found that 48% of patients receiving TMC207 in combination with standard treatment converted to negative sputum culture after eight weeks compared with 9% of those who received placebo and standard treatment.
TB is among the leading causes of death among people living with HIV, and accounts for an estimated 23% of AIDS deaths worldwide.